Originally published December 28, 2007 at 12:00 AM | Page modified December 28, 2007 at 12:35 AM
Biotech finalizes cancer drug purchase
In a bid to once again become a biotech company with marketed products, Cell Therapeutics said Thursday it completed its purchase of U.S. rights to the cancer...
Seattle Times business reporter
In a bid to once again become a biotech company with marketed products, Cell Therapeutics said Thursday it completed its purchase of U.S. rights to the cancer drug Zevalin for $10 million.
The therapy is now approved only for treating a common form of blood cancer called relapsed indolent non-Hodgkins lymphoma.
The Seattle biotech will pay an additional $20 million to Biogen-Idec, the therapy's developer, if the U.S. Food and Drug Administration approves it for certain other non-Hodgkins lymphoma applications. Cell Therapeutics will also pay sales royalties until at least December 2015, a statement said.
Zevalin, which in 2006 had U.S. sales of $16.4 million, uses antibodies to deliver radiation directly to cancer cells.
Despite promising data about its effectiveness, oncologists prescribe Zevalin to fewer than 1,000 U.S. patients annually because it must be administered in institutions able to deal with radiation, said Cell Therapeutics Chief Executive James Bianco.
Cell Therapeutics plans an educational and marketing blitz to persuade doctors to adopt the therapy. If it succeeds, Zevalin profits could pay for the development of the company's other products, Bianco said.
"If this product does 50 million or 60 million [dollars] a year — that could fund our entire operations," he said.
Cell Therapeutics has had no commercial products since it sold off Trisenox in 2005. The federal government accused Cell Therapeutics of promoting the drug for unapproved uses, a claim that the company settled earlier this year by paying $10.5 million.
The company now plans to concentrate on growing Zevalin's market share and getting its two leading drug candidates, Xyotax and Pixantrone, to market. Last August, Cell Therapeutics said that it had run up $1 billion in losses since its inception 16 years ago.
Ángel González: 206-515-5644 or agonzalez@seattletimes.com
Copyright © 2007 The Seattle Times Company
An 802.11n upgrade could make a big difference
Retailers opening doors on Thanksgiving Day
Google makes concessions on digital book deal
Critics want to block Comcast-NBC deal
Google submits revised book settlement

Opening day at Crystal Mountain
Skiers crowded the slopes at Crystal Mountain for one of the resort's earliest openings.
nwjobs

Post a comment

Michelle Goodman blogs about work/life balance.
How to tell your office you're gravely ill
Post a comment
nwautos

Choosing a new sedan? Weigh the impact of your choice on your wallet and on the planet.
Post a comment
- Homeless man, 46, arrested in Greenwood arsons
- KVI talk radio host off the air as of Thursday
- Steve Kelley | ESPN's Bill Simmons gets us: He hates Clay Bennett, too
- Police investigate videotaped arrest
- Seattle U. Men's Hoops | Big recruit goes from Huskies to Redhawks
- Razor found in muffin an accident, 'mortified' baker says
- Mariners sign Jack Wilson to 2-year contract
- Suspect's family shaken by slaying of police officer
- Mountlake Terrace woman reports razor in muffin
- Ivar's undersea billboards a hoax devised as marketing ploy
- Police investigate videotaped arrest
631 - Seattle man to pack a pistol into community center to protest mayor's ban
202 - Light rail to airport to begin Dec. 19
177 - GOP clueless as families struggle with health care
166 - KVI talk radio host off the air as of Thursday
134 - Mariners sign Jack Wilson to 2-year contract
120 - Prosecutor weighs death penalty in police slaying
103 - Wright State game thread
97 - Person of interest in custody in connection with Greenwood arsons
95 - Rang says Locker not ready for NFL
85
- Light rail to airport to begin Dec. 19
- Homeless man, 46, arrested in Greenwood arsons
- Ivar's undersea billboards a hoax devised as marketing ploy
- Steve Kelley | ESPN's Bill Simmons gets us: He hates Clay Bennett, too
- Washington in race for federal education funds
- KVI talk radio host off the air as of Thursday
- Police investigate videotaped arrest
- Goodwill's Glitter Sale is Nov. 14-15
- Boeing: 787 fix is complete on first plane
- Seattle U. Men's Hoops | Big recruit goes from Huskies to Redhawks





